Haidian Maternal and Child Healthcare Hospital
Welcome,         Profile    Billing    Logout  
 10 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Qi
NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

Recruiting
4
100
RoW
Tenofovir Alafenamide 25 MG, Vemlidy
New Discovery LLC, Beijing Ditan Hospital
Hepatitis B, Chronic
09/23
09/23
APPROACH, NCT04841811: MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.

Recruiting
3
192
RoW
Almonertinib, ctDNA dynamic monitoring guided the Almonertinib treatment
Guangdong Association of Clinical Trials, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer
12/24
12/26
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

Active, not recruiting
3
330
RoW
SHR0302, Placebo
Reistone Biopharma Company Limited
Alopecia Areata
10/23
02/24
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Active, not recruiting
3
920
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
NCT06123858: Non-alcoholic Steatohepatitis Registry Platform Study

Recruiting
N/A
2500
RoW
AstraZeneca
NASH With Fibrosis
12/26
12/26
Jin, lei
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Qi
NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

Recruiting
4
100
RoW
Tenofovir Alafenamide 25 MG, Vemlidy
New Discovery LLC, Beijing Ditan Hospital
Hepatitis B, Chronic
09/23
09/23
APPROACH, NCT04841811: MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.

Recruiting
3
192
RoW
Almonertinib, ctDNA dynamic monitoring guided the Almonertinib treatment
Guangdong Association of Clinical Trials, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer
12/24
12/26
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

Active, not recruiting
3
330
RoW
SHR0302, Placebo
Reistone Biopharma Company Limited
Alopecia Areata
10/23
02/24
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Active, not recruiting
3
920
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
NCT06123858: Non-alcoholic Steatohepatitis Registry Platform Study

Recruiting
N/A
2500
RoW
AstraZeneca
NASH With Fibrosis
12/26
12/26
Jin, lei
No trials found

Download Options